Notable Labs assists doctors in identifying personalized combinations of FDA-approved treatments for cancer patients. Notable is focused on individual patients and using existing treatments, they are exploring new indications of drugs and identifying mechanisms underlying cancer progression and drug resistance. Using robotic and modern data science, Notable is developing a scalable, iterative model that will turn individual treatment selection into a quantifiable problem.
Notable has formed several clinical trial partnerships with health centers and hospitals, including but not limited to:
- The University of Kansas Medical Center
- Orlando Health
- UHN Princess Margret Cancer Centre
- The University of Texas, MD Anderson Cancer Center
- UCSF Hellen Diller Family Comprehensive Cancer Center
Notable has published numerous cancer research studies with various organizations, many of which have been made available for public reading.
Timeline
Notable's The ANSWer Study
Notable and MDS Foundation Announce Partnership on Clinical MDS Trials and Drug Therapies for MDS Patients
Notable, announces its board has appointed life science executive, Laurie Heilmann, as Chief Executive Officer.
Notable Labs launches rolling blood cancer trial to test its AI system
Notable Labs has a post-money valuation in the range of $100M to $500M as of Jul 16, 2019 according to PrivCo.
Notable Labs raises a $40,000,000 series B round from 11.2 Capital, Y Combinator, LifeForce Capital, Founders Fund, First Round Capital, B Capital Group and Industry Ventures.
Notable Labs raises a $14,800,000 series B round from Kevin Mahaffey, LifeForce Capital and Builders VC.
Notable Labs raises a $6,000,000 seed round from Wei Guo, Y Combinator, OS Fund, AME Cloud Ventures, Founders Fund, Eric Kwan, Khosla Ventures, Refactor Capital, Data Collective, Threshold Ventures and First Round Capital.
Funding rounds
Series B round
Y Combinator
Founders Fund
First Round Capital
Industry Ventures
11.2 Capital
LifeForce Capital
B Capital Group
Kevin Mahaffey
Builders VC
Series A round
DTRIBE Capital
Alumni Ventures Group
Khosla Ventures
OS Fund
Data Collective
Refactor Capital
AME Cloud Ventures
Threshold Ventures
Eric Kwan
Amasia
Great Oaks Venture Capital
Fuel CapitalPeople
Hiroomi Tada, M.D., Ph.D.
Cheif Medical Officer
Kathryn Vanderlaag
Senior Director, Biology and Assay Development
Further reading
Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-positive AML Defines Novel Therapeutic Options - A COG and TARGET Pediatric AML Study
Jenny L. Smith, Rhonda E. Ries, Tiffany Hylkema, Todd A Alonzo, Robert B Gerbing, Marianne T. Santaguida, Lisa Eidenschink Brodersen, Laura Pardo, Carrie L Cummings, Keith R Loeb, Quy Le, Suzan Imren, Amanda R Leonti, Alan S. Gamis, Richard Aplenc, E Anders Kolb, Jason E. Farrar, Timothy J. Triche, Cu Nguyen, Daoud Meerzaman, Michael R Loken, Vivian G. Oehler, Hamid Bolouri and Soheil Meshinchi
Web
Notable Labs lands $40M to expand AI-based cancer treatment tech
Amirah Al Idrus
Web
July 16, 2019
Documentaries, videos and podcasts
Companies
References
Notable Labs
CompanyCompany attributes
Brain
Biotechnology
Cancer
Laboratory
Healthcare
Drug discovery
Medical diagnostics
San Francisco
Matt De Silva
Peter Quinzio
Laurie Heilmann
Emerald Cloud LabCategories
Related Topics
Contributors
- 1
Erin Scherfner
Golden - Writer & Contributor, Fortuity Partners - Director of Marketing & Communications - 2
Melanie Manipula
Researcher, writer and a former librarian - 3
Dawson Sewell
Seeking to explain science and technology through simple writing. - 4
Neelam Jhaveri
Techno Geek + Gamer + Fashionista + Sense of Humor = It's ME